Executive Summary: EHC Round Table on “Current Issues in von Willebrand Disease”

On 10 September 2024, the EHC hosted its first post-pandemic Round Table on “Current Issues in von Willebrand Disease” in Brussels, Belgium. The event took place at the Warwick Hotel from 13:00 to 16:30, and was co-chaired by Miguel Crato, EHC President, and Dr Maria Elisa Mancuso, Chair of the EHC Medical Advisory Group.

The Round Table was attended by a diverse group of stakeholders. This included EHC staff and Steering Committee members, National Member Organisation (NMO) representatives, and members of the EHC Von Willebrand Disease (VWD) Committee. In addition, third-party organisations such as the European Association for Haemophilia and Allied Disorders (EAHAD), clinicians, and industry representatives were present.

The variety of attendees fostered rich discussions and allowed for a broad exchange of perspectives on the key challenges and opportunities in VWD care.

Read the Round Table Executive Summary

Other resources

Update on Novo Nordisk manufacturing deviation for NovoSeven©, resulting in shortages for NovoEight© and Esperoct©

Mid-June 2024, the EHC, NBDF and WFH were made aware of a manufacturing deviation in the production lines of several products for the treatment of haemophilia and other coagulopathies manufactured by Novo Nordisk in Denmark.

Find Out More

Let’s celebrate INSD together: neonatal screening for rare diseases could save lives

On the occasion of International Neonatal Screening Day (INSD) 2024, the EHC joins the Screen4Rare initiative in celebrating the importance of neonatal screening for those living with a treatable rare disease.

Find Out More